SEC Form 4 · accession 0001209191-18-017693
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Haig P. Bozigian
Officer — Chief Development Officer
Period of report
Mar 5, 2018
Accepted (ET)
Mar 7, 2018 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 5, 2018 | M | 61,474 | $5.76 | A | 197,471 | D | |
| Common Stock | Mar 5, 2018 | S | 61,474 | $90.00 | D | 135,997 | D | |
| Common Stock | Mar 5, 2018 | M | 14,399 | $43.24 | A | 150,396 | D | |
| Common Stock | Mar 5, 2018 | S | 14,399 | $90.00 | D | 135,997 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2 | $5.76 | Mar 5, 2018 | M | 61,474 | A | — | Aug 25, 2021 | Common Stock | 61,474 | 18,243 | D |
| Non-Qualified Stock OptionF3 | $43.24 | Mar 5, 2018 | M | 14,399 | A | — | Feb 6, 2027 | Common Stock | 14,399 | 59,460 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011.
- F3Option granted February 06, 2017 and vested monthly over four years.